Lunit, a pioneer in AI-powered cancer solutions, has set a new benchmark with its INSIGHT MMG tool in a groundbreaking step toward improving breast cancer screenings, Medical Device Network reports.
Using artificial intelligence, this cutting-edge technology outperformed human radiologists in detecting breast cancer, marking a significant advancement in medical diagnostics.
Lunit's INSIGHT MMG, an AI tool for breast cancer screening, matches human radiologists' accuracy, revolutionizing diagnostics and prompting integration into standard protocols.
AI Accuracy with Breast Cancer Screenings
A recent study conducted in Denmark, spanning mammography screenings on over 149,000 women between August 2014 and August 2018, showcased the prowess of Lunit's INSIGHT MMG.
The study meticulously evaluated key metrics: correctly identifying cancer-free exams, diagnosing cancer, positive predictive value, and recall rate.
Astonishingly, the AI tool demonstrated comparable accuracy to human radiologists, albeit with marginal differences-slightly lower specificity, positive predictive value, and a marginally higher recall rate.
When the tool's cut-off score aligned with the average sensitivity of the initial reader, it demonstrated a marginally reduced specificity (97.5% compared to 97.7%), positive predictive value (17.5% versus 18.7%), and a slightly elevated recall rate (3% versus 2.8%) in comparison to human radiologists.
Read Also: Microautophagy: Study Reveals How Cells Repair Damaged Lysosomes, Defy Aging
The Future of Breast Cancer Screening Protocols
What sets INSIGHT MMG apart is its ability to act as an independent reader, an FDA-cleared and CE-marked technology interpreting mammograms with precision that enhances productivity in clinical settings.
These findings are not just a testament to the potential of AI in healthcare but also a boon for radiologists, easing their workload while significantly improving cancer detection rates.
Moreover, the study's implications are profound. It's paving the way for the integration of AI into standard breast cancer screening protocols.
Lunit's CEO, Brandon Suh, emphasizes this groundbreaking potential, highlighting how INSIGHT MMG does not just promise better detection rates but also valuable support for radiologists in their crucial work.
Private Partnerships
Taking this innovation a step further, Lunit has inked a monumental partnership with Capio St Göran, Sweden's largest private hospital.
This collaboration marks a historic shift as it becomes the world's first breast center to incorporate AI as an independent reader.
The integration of INSIGHT MMG into their screening process for nearly 78,000 patients annually is a giant leap towards optimizing operational efficiency and enhancing patient experiences.
Dr. Fredrik Strand, leading the transformative study at the Karolinska Institutet in Sweden, believes that AI's role as a supplementary reader can significantly reduce medical costs and streamline healthcare reimbursement, easing the strain caused by the scarcity of radiologists.
These strides in AI adoption in healthcare align with a global trend. Industry forecasts, such as the predictions by GlobalData, hint at a growing adoption of AI technology across medical devices to elevate diagnostic precision and treatment predictions.
This monumental breakthrough will be presented at the upcoming EUSOBI 2023 conference, sharing its potential to redefine standards in breast cancer screening.
Stay posted here at Tech Times.
Related Article: 3D Mini Human Colons With Immune Cells Developed to Advance Treatments for Colon-Related Diseases
